Esbriet

Active substance

pirfenidone

Holder

NV Roche SA

Status

Running

Indication

treatment of patients with advanced idiopathic pulmonary fibrosis and risk of group 3 pulmonary hypertension (i.e. pulmonary hypertension occurring secondary to lung disease and/or hypoxia) and exiting study MA29957

Public documents

Approbation

Information for the patient

Informed consent

Last update

26/06/2020
Last updated on 13/04/2021